Furthermore, this investigation tackled the obstacles associated with assessing functionality and determining the pathogenicity of new BRCA1 variants, which are known to substantially elevate the risk of breast and ovarian cancers and are typically identified through clinical genetic testing. This evidence concerns the gene BRCA1 and ovarian carcinoma.